Chimectin as a novel wound biologic for xylazine-induced tissue injury
About This Grant
Abstract The opioid epidemic has led to widespread morbidity and mortality, with xylazine, an animal sedative, emerging as a common adulterant in illicit opioids. Xylazine causes severe skin ulceration and necrosis due to its vasoconstrictive effects, resulting in impaired tissue oxygenation and chronic vascular damage. This project aims to develop Chimectin, a first-in- class fibronectin matrix mimetic, as a novel therapeutic to accelerate healing of xylazine- induced skin injuries. Chimectin, a recombinant fibronectin fragment, mimics the structural and functional properties of native fibronectin fibrils, stimulating local vasodilation and promoting revascularization of wounds. In preclinical studies, Chimectin accelerated healing of excisional wounds in a diabetic mouse model. The proposed research will first develop a topical formulation of Chimectin, followed by testing its efficacy in an established preclinical model of ischemic skin ulcers to mimic xylazine-induced vascular damage. The Chimectin formulation will undergo stability and performance testing, with wound healing efficacy evaluated at different concentrations (10, 20, and 40 µM). Successful outcomes will provide the foundation for advancing Chimectin toward clinical development for xylazine-induced and other chronic skin wounds. This innovative therapy aims to address a critical unmet medical need and has the potential to reduce the significant healthcare burden associated with chronic wound management.
Grant Summary
Chimectin as a novel wound biologic for xylazine-induced tissue injury is a NIDA - National Institute on Drug Abuse grant providing up to $274K for university, nonprofit, healthcare org. Applications are due 2027-05-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $274K
2027-05-31
- 1Confirm your organization is eligible for Chimectin as a novel wound biologic for xylazine-induced tissue injury from NIDA - National Institute on Drug Abuse, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIDA - National Institute on Drug Abuse before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIDA - National Institute on Drug Abuse's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Chimectin as a novel wound biologic for xylazine-induced tissue injury: Frequently Asked Questions
Who is eligible for the Chimectin as a novel wound biologic for xylazine-induced tissue injury?
Chimectin as a novel wound biologic for xylazine-induced tissue injury is offered by NIDA - National Institute on Drug Abuse and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Chimectin as a novel wound biologic for xylazine-induced tissue injury provide?
Chimectin as a novel wound biologic for xylazine-induced tissue injury provides up to $274K per award from NIDA - National Institute on Drug Abuse. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Chimectin as a novel wound biologic for xylazine-induced tissue injury deadline?
Applications for Chimectin as a novel wound biologic for xylazine-induced tissue injury are due 2027-05-31 (open). Because deadlines can change, verify the date with the funder, NIDA - National Institute on Drug Abuse, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Chimectin as a novel wound biologic for xylazine-induced tissue injury?
To apply for Chimectin as a novel wound biologic for xylazine-induced tissue injury, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIDA - National Institute on Drug Abuse.